Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia
Latest Information Update: 28 Mar 2025
At a glance
- Drugs Plozasiran (Primary)
- Indications Hypertriglyceridaemia
- Focus Registrational; Therapeutic Use
- Acronyms MUIR-3
- Sponsors Arrowhead Pharmaceuticals
Most Recent Events
- 27 Apr 2024 Status changed from not yet recruiting to recruiting.
- 09 Apr 2024 New trial record